Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)

Drug	Drug Name	Drug Description
DB00242	Cladribine	A purine antimetabolite used for the management of relapsing forms of Multiple Sclerosis (MS), used in patients who have not responded to or who were unable to tolerate alternative MS drugs.

Drug	Drug Name	Target	Type
DB00242	Cladribine	Purine nucleoside phosphorylase	target
DB00242	Cladribine	DNA	target
DB00242	Cladribine	Deoxycytidine kinase	enzyme
DB00242	Cladribine	Ribonucleoside-diphosphate reductase large subunit	target
DB00242	Cladribine	Ribonucleoside-diphosphate reductase subunit M2	target
DB00242	Cladribine	Ribonucleoside-diphosphate reductase subunit M2 B	target
DB00242	Cladribine	DNA polymerase alpha catalytic subunit	target
DB00242	Cladribine	DNA polymerase epsilon catalytic subunit A	target
DB00242	Cladribine	DNA polymerase epsilon subunit 2	target
DB00242	Cladribine	DNA polymerase epsilon subunit 3	target
DB00242	Cladribine	DNA polymerase epsilon subunit 4	target
DB00242	Cladribine	ATP-binding cassette sub-family G member 2	transporter
DB00242	Cladribine	Solute carrier family 28 member 3	transporter

Drug	Drug Name	Phase	Status	Count